2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Artificial Intelligence (AI), Computer Vision, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Apoptosis, Genomics, Microbiome, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality Improvement, Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

5658 Progression-free survival of pirtobrutinib versus ibrutinib in previously untreated CLL/SLL: A covariate-adjusted pooled analysis of BRUIN CLL-313 and CLL-314

Catherine C. Coombs, MD, Farrukh T Awan, M.D.M.S.,M.B.A.2, Mazyar Shadman, MD, MPH3, Yuanyuan Bian4, Manoj Khanal5, Weiji Su6, Naleen Raj Bhandari, Ph.D7, Amy S. Ruppert Stark, PhD8, Ching Ching Leow, PhD9, Huseini Kagdi, MD, PhD, MBBS, FRCPath, MRCP10, Rodrigo Ito11, Min-Hua Jen, PhD12, Wojciech Jurczak, MD, PhD13
1 University of California Irvine, Irvine, California, United States
2 University of Texas Southwestern Medical Center, Dallas, Texas, United States
3 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
4 Eli Lilly and Company, Indianapolis, Indiana, United States
5 Eli Lilly and Company, Indianapolis, Indiana, United States
6 Eli Lilly and Company, Indianapolis, Indiana, United States
7 Eli Lilly and Company, Indianapolis, Indiana, United States
8 Eli Lilly and Company, Indianapolis, Indiana, United States
9 Eli Lilly and Company, Indianapolis, Indiana, United States
10 Eli Lilly and Company, Indianapolis, Indiana, United States
11 Eli Lilly and Company, Indianapolis, Indiana, United States
12 Eli Lilly and Company, Indianapolis, Indiana, United States
13 Maria Sklodowska-Curie National Institute of Oncology, Krakow, Poland

Background: BRUIN CLL-313 (NCT05023980) demonstrated superior progression-free survival (PFS) for pirtobrutinib vs bendamustine plus rituximab in patients (pts) with previously untreated chronic lymphocytic leukemia (CLL) (Jurczak, J Clin Oncol 2025). BRUIN CLL-314 (NCT05254743) showed a favorable early PFS trend for pirtobrutinib vs ibrutinib in a subgroup of pts with untreated CLL (Woyach, J Clin Oncol 2025). A recent Bayesian network meta-analysis comparing guideline-recommended first-line treatments also suggested superior PFS for pirtobrutinib vs ibrutinib and comparable efficacy vs second-generation covalent Bruton tyrosine kinase inhibitors (cBTKi) (Eyre, Cancers 2026). This study further evaluated PFS in pts with previously untreated CLL receiving pirtobrutinib or ibrutinib, comparing pooled individual patient-level data from the pirtobrutinib arms of CLL-313 (n=141; data cut Apr 2026) and CLL-314 (n=112; data cut Jun 2025) with the ibrutinib arm of CLL-314 (n=113). 
Methods: Previously untreated pts with CLL who were randomized to receive pirtobrutinib in CLL-313 or CLL-314 or ibrutinib in CLL-314 were eligible for this pooled analysis, which followed a 2-stage approach. Potential imbalances in baseline characteristics between treatment groups were adjusted using propensity score weighting (PSW; logistic regression and generalized boosted models), propensity score matching (PSM; 2:1 matching), and entropy balancing. Covariates adjusted were age; del(17p), TP53 mutation, and IGHV mutation status; complex karyotype (≥3 abnormalities); Rai stage; bulky disease (≥5 cm); β2 microglobulin (>3.5 mg/L); and region. Covariate balance based on standardized mean differences (SMD) and pirtobrutinib effective sample size (ESS) were assessed to prespecify which covariate-adjusted method would serve as the primary vs sensitivity analysis for PFS comparison. PFS assessed by independent review committee, defined as the time from random assignment until first occurrence of disease progression or all-cause death, was compared using Kaplan-Meier methods in the covariate-adjusted population, and hazard ratios (HRs) with 95% confidence intervals (CIs) for pirtobrutinib vs ibrutinib were estimated using Cox proportional hazards models with method-appropriate variance estimation. Statistical significance was defined as 2-sided p≤0.05, with no multiplicity adjustment. 
Results: The pooled dataset included 253 and 113 pts treated with pirtobrutinib and ibrutinib, respectively. Before adjustment, mean (standard deviation) age was 65.2 (10.2) vs 65.2 (10.3) years and the proportions of pts with del(17p), TP53 mutation, and mutated IGHV were 6.7% vs 13.3%, 8.3% vs 16.8%, and 39.1% vs 34.5% for pirtobrutinib and ibrutinib, respectively. Baseline characteristics were well-balanced after adjustment with all 4 methods. PSW with logistic regression achieved optimal covariate balance with SMD<0.1 for all covariates, without meaningful ESS reduction and therefore, served as primary analysis; remaining methods served as sensitivity analyses. Across all analyses, pirtobrutinib was associated with a lower risk of progression or death than ibrutinib. The unadjusted analysis yielded a HR (95% CI) of 0.35 (0.18–0.67; p=0.002) with median PFS not estimable in either group; 24-month PFS rates (95% CIs) were 92.1% (88.7%–95.7%) for pirtobrutinib and 84.2% (77.3%–91.6%) for ibrutinib. PSW using logistic regression (ESS=183.6) produced a HR of 0.36 (0.17–0.76; p=0.007). Sensitivity analyses showed similar results: PSW using generalized boosted models (ESS=171.9): HR 0.35 (0.17–0.70; p=0.003); PSM (ESS=177.9): HR 0.34 (0.15–0.74; p=0.007); and entropy balancing (ESS=182.0): HR 0.38 (0.18–0.81; p=0.01). 
Conclusion: Pirtobrutinib was associated with statistically significant improvement in PFS vs ibrutinib across all 4 analytic approaches in this pooled analysis of pts with previously untreated CLL. These findings alongside published evidence support pirtobrutinib as a reasonable first-line treatment option for consideration. Given many pts with CLL may receive only 1-2 lines of therapy in the modern era, early utilization of the most efficacious and tolerable treatment may best serve pts interest. These findings should be interpreted in the context of key limitations, including lack of direct trial comparison with second-generation cBTKi and residual between-trial differences that may not be fully accounted for by the analytic approaches implemented.

Catherine C. Coombs, MD: Geron - Stock (publicly traded); Lilly - Honoraria; AstraZeneca - Honoraria; Johnson and Johnson - Honoraria; BeOne - Honoraria; AbbVie - Honoraria; Genentech - Honoraria; BMS - Honoraria; CarnaBio - Research Funding; AbbVie - Research Funding; Lilly - Research Funding; AstraZeneca - Research Funding; BeOne - Research Funding; BeOne - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Pharmacyclics - Consultancy (Includes expert testimony); Lilly - Consultancy (Includes expert testimony); Allogene - Consultancy (Includes expert testimony); Invivyd - Consultancy (Includes expert testimony)